权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Project 2

项目2

基本信息

批准号：
10666673
负责人：
ALAN D FRANKEL
金额：
$ 152.92万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-15 至 2027-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10666673
关键词：
Address Architecture Binding Biochemical Biological Assay CD4 Positive T Lymphocytes CRISPR/Cas technology Carrier Proteins Cell Line Cell Separation Cell model Cells Chromatin Chromatin Remodeling Factor Chronic Clonal Expansion Complex Cryoelectron Microscopy Development Dimerization Drug Targeting Evolution Gene Expression Genetic Genetic Transcription HIV HIV-1 HIV-2 HIV/AIDS Heterochromatin Histones Individual Infection Integration Host Factors Introns Link Lymphocyte Macrophage Maintenance Messenger RNA Modeling Modification Molecular Molecular Conformation NF-kappa B NFKB Signaling Pathway Nuclear Export Nuclear Pore Complex Proteins Pathway interactions Peptides Phase Play Positive Transcriptional Elongation Factor B Post-Translational Protein Processing Process Property Protein Isoforms Proteins Proteomics Provirus Integration RNA RNA Binding RNA Splicing RNA Transport Regulation Reporter Reporting Research Priority Resolution Response Elements Rest Role Running SIV Shock Signal Transduction Site Small Nuclear Ribonucleoproteins Structure TRAF6 gene Testing Time Transcript Transcription Elongation Transcription Initiation Ubiquitination United States National Institutes of Health Viral Viral Genes Virus Virus Integration Virus Replication X-Ray Crystallography biophysical techniques dimer experimental study genetic analysis genetic regulatory protein genomic locus inhibitor integration site latent HIV reservoir latent infection lonely individuals mRNA Export mRNA Translation monocyte mutant mutation screening novel promoter recruit stem structural biology synergism tat Protein transcription factor ubiquitin ligase ubiquitin-protein ligase viral RNA

项目摘要

THE HARC CENTER: HIV ACCESSORY AND REGULATORY COMPLEXES PROJECT 2: REGULATION OF HIV TRANSCRIPTION AND LATENCY SUMMARY The HIV regulatory proteins Tat and Rev play a crucial role in controlling HIV transcription and mRNA export, respectively. In Project 2, we will functionally and structurally elucidate the roles of ubiquitin ligases that modify Tat, reveal the architecture of the Rev/RRE nuclear export complex to understand the mechanisms regulating HIV mRNA translation, and compare Rev and RRE evolution in SIV and HIV to identify viral factors that contribute to zoonosis. To achieve this, we will determine the functional interactions between the E3 ligases UBE2O and TRAF6 with Tat by cryo-EM or X-ray crystallography (Structural Biology Core) and investigate the mechanism by which UBE2O promotes the release of the inhibitory 7SK snRNP by ubiquitination of the HEXIM1 subunit. We will determine the high-resolution structure of the Rev/RRE/Crm1/RanGTP nuclear export complex by cryo- EM and define genetic and protein interaction landscapes of the Rev/RRE complex. We will also compare its protein-protein and protein-RNA interfaces between HIV-1, HIV-2, and SIV complexes. We will use the HEPS platform (Genetics core, Proteomics core and Structural biology core) and deep mutational scanning to functionally validate these interactions and define them biochemically and structurally. The latent HIV reservoir represents a significant roadblock to eradicating infection. We aim to uncover factors that drive HIV latency, including virus integration sites and the states of chromatin and chromatin interacting proteins. Using CRISPR-Cas9 (Genetics core), we will integrate a minimal HIV-1 LTR reporter into CD4+ T cells to address how integration into specific genomic loci may permit expansion of particular clonal cells without virus expression, to understand mechanistically how a large fraction of latent cells expand in chronically infected individuals over time. Using proteomics and a variety of biochemical and biophysical methods, we will identify post-translational modifications on HP1 proteins, test the roles of specific HP1 modifications on their phase- separation properties, and assess site-specific HP1 mutants for virus replication. This will elucidate how the state of chromatin and heterochromatin impact HIV transcription. Finally, we will examine the role of non-canonical (nc) NF-kB in enhancing latency reversal for shock-and-kill therapies. We will assess synergies between inhibition of SAMHD1 and of the ncNF-kB pathway in latency reversal in monocytic and lymphocytic latent cell models, resting CD4+ T cells (the major reservoir of latent HIV), and gut macrophages isolated from people living with HIV (PLWH). In summary, Project 2 will uncover potential new interfaces as HIV drug targets and evaluate latency reversal or induction of deep latency for cure strategies.

硬中心：HIV附属和调控复合物